Viewing nowSitagliptin Tablet 25mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 28.34mg
Tablet · Prescription medication
TDS Pharm Co., Ltd.

MFDS item code 202301860 · Approved 2023.06.19 · Insurance code 679802250
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise strategies to assist patients with type 2 diabetes in controlling their blood sugar levels. It can be administered alone when starting treatment for the first time. If there has been no prior experience with diabetes treatment and blood sugar is not well controlled with monotherapy, it may be used in conjunction with metformin. Additionally, it is combined when blood sugar control is insufficient with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin. This medication can enhance therapeutic effects even when blood sugar control remains challenging despite multiple drugs. Thus, it improves blood sugar control in patients with type 2 diabetes across various conditions.
This medicine is administered at 100 ㎎ once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 ㎎. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Because dosage adjustment according to renal function is required, renal function should be assessed before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 ㎖/min/1.73 ㎡ and < 90 ㎖/min/1.73 ㎡). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 ㎖/min/1.73 ㎡ and < 60 ㎖/min/1.73 ㎡). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 ㎖/min/1.73 ㎡ and < 45 ㎖/min/1.73 ㎡), administer 50 ㎎ once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 ㎖/min/1.73 ㎡ and < 30 ㎖/min/1.73 ㎡) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 ㎖/min/1.73 ㎡), administer 25 ㎎ once daily. This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions after administration; if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a physician. During the use of this medication, serious pancreatic inflammation (acute pancreatitis) may occur; thus, any symptoms such as abdominal pain or vomiting should be reported to medical personnel immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication; it should also be avoided in individuals with allergies to this drug or its components. Patients with impaired kidney function must have their dosage adjusted for this medication, so those with renal disease should consult their healthcare provider. In clinical trials, patients taking this medication primarily reported side effects such as upper respiratory tract infections, headaches, nasopharyngitis, and diarrhea, while the risk of hypoglycemia may increase, particularly when used in combination with insulin or sulfonylureas. This medication can cause symptoms of hypoglycemia when taken with other antidiabetic agents, thus dose adjustments may be necessary when taken with insulin or sulfonylureas. Severe joint pain or blistering skin diseases may occur; if these symptoms appear, inform your physician immediately and stop taking the medication. This medication generally has fewer interactions with certain drugs, but caution is needed when taken with cyclosporine or digoxin, and monitoring by medical personnel is required. Pregnant or breastfeeding women are advised not to take this medication, and its use in patients under 18 years of age should be avoided due to the lack of established safety and efficacy. Elderly patients may have reduced kidney function, thus regular kidney function tests are important before and after taking this medication. In cases of overdose, unabsorbed medication should be removed, and clinical monitoring including cardiac condition should be performed; if necessary, some medications can be removed through hemodialysis.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture exposure, ideally at room temperature between 1°C and 30°C. This helps maintain its effectiveness and ensures safe use.
Bright yellow-orange round film-coated tablet
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 28.34mg
Tablet · Prescription medication
TDS Pharm Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.